methylprednisolone sodium succinate

He received intensive multimodal immunotherapy, including high-dose methylprednisolone, intravenous immunoglobulin, plasma exchange, and rituximab. This is the first report of a seizure-free, triple-positive autoimmune encephalitis subtype presenting with prominent cognitive impairment, thereby expanding the clinical spectrum of recently described overlapping autoimmune encephalitis syndromes. The low titer and rapid seroreversion of mGluR5 antibodies suggest a possible bystander phenomenon secondary to blood-brain barrier disruption.

High-dose intravenous methylprednisolone therapy resulted in marked clinical improvement. The absence of intrathecal IgG synthesis raises the possibility that pathogenic antibodies were predominantly derived from the peripheral compartment. These findings underscore the pharmacodynamic limitations of FcRn inhibition, particularly in the setting of thymoma-associated immune dysregulation.

P=N/A, N=80, Recruiting, China-Japan Friendship Hospital | Not yet recruiting --> Recruiting | Initiation date: Feb 2026 --> May 2026

P3, N=210, Recruiting, Oculis

P2, N=60, Active, not recruiting, Cynata Therapeutics Limited | Recruiting --> Active, not recruiting

P2, N=60, Not yet recruiting, Sun Yat-sen University

P3, N=198, Recruiting, Tianjin Medical University General Hospital | Phase classification: P4 --> P3

P=N/A, N=1000, Recruiting, Assiut University | N=30 --> 1000 | Trial completion date: May 2026 --> Feb 2027 | Trial primary completion date: May 2026 --> Jan 2027

P1/2, N=13, Active, not recruiting, Prevail Therapeutics Inc. | Suspended --> Active, not recruiting

P3, N=50, Active, not recruiting, The Hospital for Sick Children | Recruiting --> Active, not recruiting | Trial completion date: Nov 2026 --> Feb 2027

P3, N=540, Recruiting, University of Sydney | Not yet recruiting --> Recruiting

P2, N=400, Recruiting, University of Birmingham | Trial completion date: Jan 2026 --> Aug 2027 | Trial primary completion date: Jan 2026 --> Aug 2027